Lipid nephrotoxicity mediated by HIF-1α activation accelerates tubular injury in diabetic nephropathy

References

• Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27 Suppl 1: S79–S83. doi:10.2337/diacare.27.2007.s79.
   PubMedGoogle Scholar
• Heyman SN, Raz I, Dwyer JP, et al. Diabetic proteinuria revisited: updated physiologic perspectives. Cells. 2022;11(18):2917. doi:10.3390/cells11182917.
   PubMed Web of Science ®Google Scholar
• Wang L, Chang JH, Buckley AF, et al. Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice. Kidney Int. 2019;95(2):321–332. doi:10.1016/j.kint.2018.09.026.
   PubMed Web of Science ®Google Scholar
• Su K, Yi B, Yao BQ, et al. Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis. Pharmacol Res. 2020;156:104778. doi:10.1016/j.phrs.2020.104778.
   PubMed Web of Science ®Google Scholar
• Cansby E, Caputo M, Gao L, et al. Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease. JCI Insight. 2020;5(24):e140483. doi:10.1172/jci.insight.140483.
   PubMed Web of Science ®Google Scholar
• Rutledge JC, Ng KF, Aung HH, et al. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010;6(6):361–370. doi:10.1038/nrneph.2010.59.
   PubMed Web of Science ®Google Scholar
• Opazo-Ríos L, Mas S, Marín-Royo G, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci. 2020;21(7):2632. doi:10.3390/ijms21072632.
   PubMed Web of Science ®Google Scholar
• Thongnak L, Pongchaidecha A, Lungkaphin A. Renal lipid metabolism and lipotoxicity in diabetes. Am J Med Sci. 2020;359(2):84–99. doi:10.1016/j.amjms.2019.11.004.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Sun H, Sun Z. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN). Lipids Health Dis. 2017;16(1):126. doi:10.1186/s12944-017-0522-6.
   PubMedGoogle Scholar
• Hu ZB, Lu J, Chen PP, et al. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis. Theranostics. 2020;10(6):2803–2816. doi:10.7150/thno.40571.
   PubMed Web of Science ®Google Scholar
• Du W, Zhang L, Brett-Morris A, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017;8(1):1769. doi:10.1038/s41467-017-01965-8.
   PubMedGoogle Scholar
• Triantafyllou EA, Georgatsou E, Mylonis I, et al. Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(9):1142–1152. doi:10.1016/j.bbalip.2018.06.015.
   PubMed Web of Science ®Google Scholar
• Seo J, Yun JE, Kim SJ, et al. Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment. Pflugers Arch. 2022;474(6):591–601. doi:10.1007/s00424-022-02683-x.
   PubMed Web of Science ®Google Scholar
• Ke Q, Yuan Q, Qin N, et al. UCP2-induced hypoxia promotes lipid accumulation and tubulointerstitial fibrosis during ischemic kidney injury. Cell Death Dis. 2020;11(1):26. doi:10.1038/s41419-019-2219-4.
   PubMed Web of Science ®Google Scholar
• Sugahara M, Tanaka S, Tanaka T, et al. Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice. J Am Soc Nephrol. 2020;31(3):560–577. doi:10.1681/ASN.2019060582.
   PubMed Web of Science ®Google Scholar
• Rosenberger C, Khamaisi M, Abassi Z, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int. 2008;73(1):34–42. doi:10.1038/sj.ki.5002567.
   PubMed Web of Science ®Google Scholar
• Liu H, Li Y, Xiong J. The role of hypoxia-inducible factor-1 alpha in renal disease. Molecules. 2022;27(21):7318. doi:10.3390/molecules27217318.
   Web of Science ®Google Scholar
• Hu ZB, Ma KL, Zhang Y, et al. Inflammation-activated CXCL16 pathway contributes to tubulointerstitial injury in mouse diabetic nephropathy. Acta Pharmacol Sin. 2018;39(6):1022–1033. doi:10.1038/aps.2017.177.
   PubMed Web of Science ®Google Scholar
• Mehlem A, Hagberg CE, Muhl L, et al. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc. 2013;8(6):1149–1154. doi:10.1038/nprot.2013.055.
   PubMed Web of Science ®Google Scholar
• Catrina SB, Zheng X. Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia. 2021;64(4):709–716. doi:10.1007/s00125-021-05380-z.
   PubMed Web of Science ®Google Scholar
• Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst. 2003;95(7):516–525. doi:10.1093/jnci/95.7.516.
   PubMedGoogle Scholar
• Vinovskis C, Li LP, Prasad P, et al. Relative hypoxia and early diabetic kidney disease in type 1 diabetes. Diabetes. 2020;69(12):2700–2708. doi:10.2337/db20-0457.
   PubMed Web of Science ®Google Scholar
• Jiang N, Zhao H, Han Y, et al. HIF-1alpha ameliorates tubular injury in diabetic nephropathy via HO-1-mediated control of mitochondrial dynamics. Cell Prolif. 2020;53(11):e12909. doi:10.1111/cpr.12909.
   PubMed Web of Science ®Google Scholar
• Persson P, Palm F. Hypoxia-inducible factor activation in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(5):345–350. doi:10.1097/MNH.0000000000000341.
   PubMed Web of Science ®Google Scholar
• Nayak BK, Shanmugasundaram K, Friedrichs WE, et al. HIF-1 mediates renal fibrosis in OVE26 type 1 diabetic mice. Diabetes. 2016;65(5):1387–1397. doi:10.2337/db15-0519.
   PubMed Web of Science ®Google Scholar
• Mei S, Li L, Zhou X, et al. Susceptibility of renal fibrosis in diabetes: role of hypoxia inducible factor-1. Faseb J. 2022;36(8):e22477. doi:10.1096/fj.202200845R.
   PubMed Web of Science ®Google Scholar
• Feng X, Wang S, Sun Z, et al. Ferroptosis enhanced diabetic renal tubular injury via HIF-1alpha/HO-1 pathway in db/db mice. Front Endocrinol (Lausanne). 2021;12:626390. doi:10.3389/fendo.2021.626390.
   PubMed Web of Science ®Google Scholar
• Sundelin JP, Ståhlman M, Lundqvist A, et al. Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma. PLoS One. 2012;7(11):e48694. doi:10.1371/journal.pone.0048694.
   PubMed Web of Science ®Google Scholar
• Leinonen H, Rossi M, Salo AM, et al. Lack of P4H-TM in mice results in age-related retinal and renal alterations. Hum Mol Genet. 2016;25(17):3810–3823. doi:10.1093/hmg/ddw228.
   PubMed Web of Science ®Google Scholar
• Cai T, Ke Q, Fang Y, et al. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1alpha-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis. 2020;11(5):390. doi:10.1038/s41419-020-2544-7.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011–1022. doi:10.1056/NEJMoa1901713.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001–1010. doi:10.1056/NEJMoa1813599.
   PubMed Web of Science ®Google Scholar
• Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021;32(3):737–755. doi:10.1681/ASN.2020081150.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9(1):47–71. doi:10.1146/annurev-pathol-012513-104720.
   PubMedGoogle Scholar
• Takkavatakarn K, Thammathiwat T, Phannajit J, et al. The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis. Clin Kidney J. 2023;16(5):845–858. doi:10.1093/ckj/sfac271.
   PubMed Web of Science ®Google Scholar